Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HIV-associated Kaposi sarcoma and related diseases
Priscila Gonçalves, Thomas S. Uldrick, Robert Yarchoan
AIDS (2017) Vol. 31, Iss. 14, pp. 1903-1916
Open Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

Kaposi sarcoma
Ethel Cesarman, Blossom Damania, Susan E. Krown, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 544
Castleman disease
Antonino Carbone, Margaret Borok, Blossom Damania, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 125
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
Jack W. Singer, Angela G. Fleischman, Suliman Al‐Fayoumi, et al.
Oncotarget (2018) Vol. 9, Iss. 70, pp. 33416-33439
Open Access | Times Cited: 127
Microbes and Cancer: Friends or Faux?
Maria Manuel Azevedo, Cidália Pina‐Vaz, Fátima Baltazar
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3115-3115
Open Access | Times Cited: 78
Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
Anna Lucia Tornesello, Maria Tagliamonte, Franco M. Buonaguro, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 227-227
Open Access | Times Cited: 67
Global trends of cancer: The role of diet, lifestyle, and environmental factors
Hassan Bahrami, Majid Tafrihi
Cancer Innovation (2023) Vol. 2, Iss. 4, pp. 290-301
Open Access | Times Cited: 24
Specific Inhibition of Viral MicroRNAs by Carbon Dots-Mediated Delivery of Locked Nucleic Acids for Therapy of Virus-Induced Cancer
Enguo Ju, Tingting Li, Zhen Liu, et al.
ACS Nano (2020) Vol. 14, Iss. 1, pp. 476-487
Open Access | Times Cited: 66
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases
Ramya Ramaswami, Kathryn Lurain, Mark N. Polizzotto, et al.
Blood Advances (2021) Vol. 5, Iss. 6, pp. 1660-1670
Open Access | Times Cited: 54
Current knowledge of immunosuppression as a risk factor for skin cancer development
María Paz Rollán, Raúl Cabrera, Robert A. Schwartz
Critical Reviews in Oncology/Hematology (2022) Vol. 177, pp. 103754-103754
Closed Access | Times Cited: 29
Reactivation of Kaposi’s sarcoma-associated herpesvirus (KSHV) by SARS-CoV-2 in non-hospitalised HIV-infected patients
Humaira Lambarey, Melissa J. Blumenthal, Abeen Chetram, et al.
EBioMedicine (2024) Vol. 100, pp. 104986-104986
Open Access | Times Cited: 9
Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma
Mark Manzano, Ajinkya Patil, Alexander Waldrop, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 57
The emerging role and significance of circular RNAs in viral infections and antiviral immune responses: possible implication as theranostic agents
Faryal Mehwish Awan, Burton B. Yang, Anam Naz, et al.
RNA Biology (2020) Vol. 18, Iss. 1, pp. 1-15
Open Access | Times Cited: 50
Primary Effusion Lymphoma: A Clinicopathological Study of 70 Cases
Zhihong Hu, Zenggang Pan, Weina Chen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 878-878
Open Access | Times Cited: 39
Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database
Muhammed Elhadi, Ala Khaled, Ahmed Msherghi
Infectious Agents and Cancer (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 35
Epidemiology of Kaposi’s sarcoma in sub-Saharan Africa
Melitah Motlhale, Freddy Sitas, Debbie Bradshaw, et al.
Cancer Epidemiology (2022) Vol. 78, pp. 102167-102167
Open Access | Times Cited: 26
Nano Drug-Delivery Systems for Management of AIDS: Liposomes, Dendrimers, Gold and Silver Nanoparticles
Fateme Davarani Asl, Marziyeh Mousazadeh, Shirinsadat Taji, et al.
Nanomedicine (2023) Vol. 18, Iss. 3, pp. 279-302
Open Access | Times Cited: 17
Applications of cell therapy in the treatment of virus-associated cancers
Keri Toner, Chase D. McCann, Catherine M. Bollard
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 709-724
Closed Access | Times Cited: 5
Unraveling lipid and inflammation interplay in cancer, aging and infection for novel theranostic approaches
Daniel Conde-Torres, Alexandre Blanco-González, Alejandro Seco-González, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma
Ajinkya Patil, Mark Manzano, Eva Gottwein
Blood (2018) Vol. 132, Iss. 6, pp. 577-586
Open Access | Times Cited: 37
Glycoprotein K8.1A of Kaposi's Sarcoma-Associated Herpesvirus Is a Critical B Cell Tropism Determinant Independent of Its Heparan Sulfate Binding Activity
Stephen J. Dollery, Rey J. Santiago-Crespo, Deboeeta Chatterjee, et al.
Journal of Virology (2018) Vol. 93, Iss. 6
Open Access | Times Cited: 35
Kaposi’s sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda
Angela Nalwoga, Romin Roshan, Kyle Moore, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 24
Immune System
Tracey L. Papenfuss, Dirk Schaudien, Chidozie J. Amuzie, et al.
Elsevier eBooks (2025), pp. 437-503
Closed Access
Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives
Nader Kim El‐Mallawany, Casey L. McAtee, Liane R. Campbell, et al.
Pediatric Health Medicine and Therapeutics (2018) Vol. Volume 9, pp. 35-46
Open Access | Times Cited: 30
Kaposi Sarcoma Rates Among Persons Living With Human Immunodeficiency Virus in the United States: 2008—2016
Qianlai Luo, Anna Satcher Johnson, H. Irene Hall, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 7, pp. e2226-e2233
Open Access | Times Cited: 25
Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial
Patricia Volkow-Fernández, Leslie Chávez‐Galán, Lucero A. Ramón‐Luing, et al.
PLoS ONE (2023) Vol. 18, Iss. 5, pp. e0280209-e0280209
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top